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Introduction: Neuropathic pain (NP) is a chronic pain modality that usually results of damage in the somatosen-
sory system. NP often shows insufﬁcient response to classic analgesics and remains a challenge to medical treat-
ment. The transcranial direct current stimulation (tDCS) is a non-invasive technique, which induces neuroplastic
changes in central nervous systemof animals and humans. The brain derived neurotrophic factor plays an impor-
tant role in synaptic plasticity process. Behavior changes such as decreased locomotor and exploratory activities
and anxiety disorders are common comorbidities associated with NP.
Objective: Evaluate the effect of tDCS treatment on locomotor and exploratory activities, and anxiety-like
behavior, and peripheral and central BDNF levels in rats submitted to neuropathic pain model.
Methods:Ratswere randomly divided: Ss, SsS, SsT, NP, NpS, andNpT. The neuropathic painmodelwas induced by
partial sciatic nerve compression at 14 days after surgery; the tDCS treatment was initiated. The animals of treat-
ed groups were subjected to a 20 minute session of tDCS, for eight days. The Open Field and Elevated Pluz Maze
tests were applied 24 h (phase I) and 7 days (phase II) after the end of tDCS treatment. The serum, spinal cord,
brainstem and cerebral cortex BDNF levelswere determined 48 h (phase I) and 8 days (phase II) after tDCS treat-
ment by ELISA.
Results: The chronic constriction injury (CCI) induces decrease in locomotor and exploratory activities, increases
in the behavior-like anxiety, and increases in the brainstem BDNF levels, the last, in phase II (one-way ANOVA/
SNK, P b 0.05 for all). The tDCS treatment already reverted all these effects induced by CCI (one-way ANOVA/
SNK, P b 0.05 for all). Furthermore, the tDCS treatment decreased serum and cerebral cortex BDNF levels and it
increased these levels in the spinal cord in phase II (one-way ANOVA/SNK, P b 0.05).
Conclusion: tDCS reverts behavioral alterations associated to neuropathic pain, indicating possible analgesic and
anxiolytic tDCS effects. tDCS treatment induces changes in the BDNF levels in different regions of the central ner-
vous system (CNS), and this effect can be attributed to different cellular signaling activations.© 2015 Elsevier Inc. All rights reserved.gia, ICBS, UFRGS, Rua Sarmento1. Introduction
Neuropathic pain, a condition of complex chronic pain, typically de-
rives from damage to the somatosensory system, which in some cases
can paradoxically lead to abnormally increased nerve activity (Treede
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pain (Florio et al., 2009). Anxiety symptoms are in fact frequently re-
ported in patients with neuropathic pain. Studies have shown that a
large number of patients with chronic pain suffer from depression or
anxiety disorders resulting from severe pain (Edwards, 2005). Animal
models of neuropathic pain have demonstrated that the level of me-
chanical sensitivity is positively correlated with anxiety behaviors
(Hasnie et al., 2007) as indexed by increased thigmotaxis in the open-
ﬁeld arena (Wallace et al., 2007). A previous study using neuropathic
pain models showed that rats exhibited mechanical hypersensitivity
and heightened anxiety-like behavior, whichwas reduced by treatment
with analgesic drugs (Roeska et al., 2009).
Recently, it has been reported that activity-dependent synaptic plas-
ticity in the spinal cord dorsal horn might be a contributive mechanism
to the development of chronic pain produced by sciatic nerve ligation in
rats (Geng et al., 2010). It has also been proposed that the brain-derived
neurotrophic factor (BDNF) has an important role in synaptic plasticity
as well as in spinal dorsal horn nociceptive information signaling
(Miletic and Miletic, 2002). Likewise, BDNF acts as a modulator in the
nociceptive response following spinal cord lesion, playing a key role in
the development of neuropathic pain after peripheral nerve injury
(Fukuoka et al., 2001). Synapseswithin each relay are under precise reg-
ulation in order to provide appropriate behavioral responses (Zhuo
et al., 2011). For example, functional andmorphological changes in neu-
ronal circuits during transcranial direct current stimulation (tDCS) seem
to require the regulation of BDNF expression (Ganguly and Poo, 2013),
and for that reason, this neurotrophin has been used as a biomarker
for cortical excitability effects on neuronal activity (Soltész et al., 2014).
Transcranial direct current stimulation is a non-invasive technique
that modulates cortical excitability in the human motor (Nitsche and
Paulus, 2000) and visual (Antal et al., 2010) cortex. This technique
modiﬁes not only the activity of cortical areas located directly under
the electrodes, but also from distant areas—probably due to primary in-
terconnections (Lang et al., 2005). The current model of tDCS effects is
based on cortico-cortical interactions, with some subcortical compo-
nents (e.g., anterior cingulate cortex and thalamic nuclei) in those cir-
cuits (Kuo et al., 2007). Clinical studies have shown that tDCS can
improve cognition performance (Utz et al., 2010) in stroke patients
(Hummel and Cohen, 2006) and chronic pain syndromes (DosSantos
et al., 2012). Studies using rats have demonstrated the effects of tDCS
on memory (Dockery et al., 2011; Li et al., 2011), Parkinson's disease,
and focal epilepsy models (Liebetanz et al., 2002). Additionally, data
from our research group revealed both immediate and long-lasting ef-
fects of repeated sessions of anodal tDCS treatment on the chronic in-
ﬂammation (Laste et al., 2012) and hyperalgesia induced by chronic
restraint stress models (Spezia Adachi et al., 2012). Considering the
effects of tDCS on pain and psychiatric disorders, the aim of this study
was to evaluate the effect of tDCS treatment on the locomotor and
exploratory activities, anxiety-like behaviors, and peripheral and central
BDNF levels of rats subjected to the neuropathic pain model over
the medium (48 h) and long term (7 days) after tDCS treatment
completion.
2. Methods
2.1. Animals
Male Wistar rats (weight, ≥250 g) aged between 55 and 65 days at
the beginning of the experiment were used. The animals (n = 144)
were randomized by weight and housed in groups of three rats per
polypropylene cage (49 × 34 × 16 cm) with sawdust-covered ﬂooring.
All animals were maintained in a controlled environment (22 ± 2 °C)
under a standard light–dark cycle (lights-on at 0700 h and lights-off at
1900 h), with water and chow (Nuvital, Porto Alegre, Brazil) ad libitum.
All experiments and procedures were approved by the Institutional
Committee for Animal Care and Use (GPPG-HCPA protocol no. 12-0514) and conformed to the Guide for the Care and Use of Laboratory
Animals (8th ed., 2011). The maintenance of the animals followed the
Brazilian law 11794, which establishes procedures for the scientiﬁc
use of animals. The experimental protocol complied with the ethical
and methodological standards of the ARRIVE guidelines (Kilkenny
et al., 2010). The experiment used the number of animals necessary to
produce reliable scientiﬁc data.2.2. Neuropathic pain model: chronic constriction injury (CCI) of the
sciatic nerve
The chronic constriction injury (CCI) of the sciatic nerve described
by Bennett andXie (1988)was used as amodel for the induction of neu-
ropathic pain. Brieﬂy, the animals were anesthetized using isoﬂurane
(5% for induction, 2.5% for maintenance) and placed in the dorsal posi-
tion for the left thigh hair shaving and skin antisepsis with 2% alcoholic
iodine (Bennett and Xie, 1988). Using aseptic techniques, the left com-
mon sciatic nerve was exposed at the middle third of the thigh by re-
moving part of the biceps femoris muscle. Close to the sciatic
trifurcation, approximately 7 mm of the ﬁrst one-third of the nerve
was released from adhering tissue and three ligatures (4-0 Vicryl)
were tied at 1mm intervals. Thus, the total length of the nerve involved
was approximately 5 mm. Ligations were loose in order to minimize
nerve constriction and allow epineural blood ﬂow. To ensure equal
level of constriction, the same investigator performed the ligatures in
all rats. After the procedure, the surgical incision was closed using 4-0
mononylon. For the sham surgery, the sciatic nerve was exposed
similarly to the CCI model, but not ligated. After surgery and anesthetic
recovery, the animals were returned to their cages, where they
remained until the day of death. The control group did not undergo
any surgical procedure.2.3. Transcranial direct current stimulation (tDCS)
Fourteen days following surgery (CCI or sham), the animals received
anodal tDCS therapy, which consisted of a constant low intensity cur-
rent (0.5 mA) applied for 20 min every afternoon during 8 days, as de-
scribed by Spezia Adachi et al. (2012). The animals remained under
light display after the completion of the application of tDCS. Notably,
this model of application required no anesthesia, unlike models used
in previous tDCS studies with rats (Liebetanz et al., 2009). In fact, this
lack of anesthesia adds strength to the study, because volatile anesthesia
(such as isoﬂurane) has been shown to decrease excitatory transmis-
sion and to increase inhibitory transmission (Ouyang and Hemmings,
2005), altering BDNF levels and, consequently, neuroplasticity (Lu
et al., 2006). Thus, we removed this confounding factor by adapting
the human model using ECG electrodes (Wachter et al., 2011) on the
rats.
The direct current was delivered from a battery-powered, constant
current stimulator using ECG electrodes with conductive adhesive hy-
drogel. The heads of the rats were shaved to improve electrode adher-
ence; the electrodes were trimmed to 1.5 cm2 surface area for better
ﬁt. The electrodes were ﬁxed to the head using adhesive tape
(Micropore™) and covered with a protective mesh to prevent removal.
The cathode was positioned at the midpoint between the lateral angles
of both eyes (supraorbital area) and the anode was placed between the
ears, on the neck of the rat (parietal cortex). This technique mirrors
tDCS protocols for humans (Nitsche et al., 2008) and has been applied
by our research group, showing antinociceptive effects (Laste et al.,
2012; Spezia Adachi et al., 2012).
For the sham stimulation, the electrodeswere placed in the samepo-
sitions as the real stimulation; however, the stimulator remained in the
“off” position throughout the procedure so as to use the same blinding
methodology as used in humans.
46 P.R.M. Filho et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 64 (2016) 44–512.4. Experimental design
The animals were acclimated to the study environment for 1 week
before the beginning of the experiment, afterwhich time theywere ran-
domly allocated into 6 groups: Sham Surgery (Ss), Sham Surgery +
Sham tDCS (SsS), Sham surgery + tDCS (SsT), Neuropathic Pain (Np),
Neuropathic Pain + Sham tDCS (NpS), and Neuropathic Pain + tDCS
(NpT). Subsequently, the surgical groups received their respective inter-
ventions (CCI or sham surgery). Fourteen days later, the hot plate test
was conducted to evaluate thermal pain sensitivity (hyperalgesia) as
an efﬁcacy control of the pain model whereby the presence of neuro-
pathic pain in the CCI groupswas veriﬁed. The animals were then treat-
ed for 8 days according to the speciﬁc protocol for each group (tDCS,
Sham-tDCS, or no treatment).
To test the effects of tDCS on the animals' behavior, the Open Field
(OF) and Plus Maze (EPM) tests were conducted at the time of tDCS
after the seventh session (Behavior test I) and one week after the last
treatment day (Behavior test II). For the biochemical assays, each
group of animals was further divided into 2 subgroups and killed at dif-
ferent timepoint treatments (at 2 and 7 days post-tDCS). Since the con-
trol group of this experiment (naive animals) obtained similar results to
the sham surgery animals in behavioral pain tests, with no statistically
signiﬁcant difference between them, we chose to use the sham surgery
as the control relative to the other groups.2.5. Open ﬁeld test (OF)
The behavioral assessment was performed in a 60 × 40 × 50 cm
varnished wooden cage with glass-lined inside walls. The linoleum
ﬂoor was divided by dark lines into twelve 13 × 13 cm squares.
Each trial started immediately after the animals were placed in the
back left corner and allowed to explore the surroundings for 5 min
(Bianchin et al., 1994; Medeiros et al., 2012). The box was cleaned be-
tween trials.
Three measures were evaluated during the test: (1) latency to leave
the ﬁrst quadrant (in seconds); (2) number of total crossings, and
(3) number of rearing behaviors (i.e., vertical activity). The number of
line crossings (all paws crossing the boundary into an adjacent
marked-out area) was taken as a measure of locomotor activity
(Roesler et al., 1999). The latency to leave the ﬁrst quadrant assessed
anxiety-like behaviors (Britton and Britton, 1981). The amount of time
the animals spent rearing (standing upright on its hind legs) (Wells
et al., 2013) was used to assess exploratory activity (Medeiros et al.,
2012). Grooming was deﬁned as the licking/washing of the head and/
or body and indicated biological functions of caring for the body surface
(Silveira et al., 2005).2.6. Elevated plus-maze test (EPM)
The elevated plus-maze test was used mainly to assess anxiety-like
behaviors. The maze was constructed using black PVC and elevated to
a height of 50 cm above ﬂoor level. The apparatus comprised two
open arms and two enclosed arms (50 × 40 × 10 cm), which extended
from a common central platform (10 × 10 cm). The animal was placed
in the EPM central area facing one of the open arms. During a 5-min ses-
sion, the following behavioral measures were recorded: (1) number of
non-protected head-dipping movements (NPHD); (2) total time spent
in the open arms (TOA), and (3) total time spent in the closed arms
(TCA). Non-protected head-dipping movements were considered to
occur when the animal dipped its head over the sides of the maze
while in an open arm. In the EPM, entering a new area was counted
when all four paws crossed into the new arm or the central area
(Rozisky et al., 2014). After each test, the apparatus was cleaned to re-
move any scent from the previously tested rat.2.7. Tissue collection
The animalswere killed by decapitation 48h (Phase I) or 7 days after
the completion of the tDCS treatment (Phase II). Central nervous system
structures (prefrontal cortex, brainstem, and spinal cord) were re-
moved and frozen at−80 °C for subsequent analysis.
2.8. BDNF assays
Blood samples were collected and centrifuged in plastic tubes for
10 min at 4500 rpm at 4 °C; the serum and plasma were stored at
−80 °C. The levels of BDNF were determined by sandwich ELISA using
monoclonal antibodies speciﬁc for BDNF (R&D Systems, Minneapolis,
United States). Total protein was measured by Bradford's method
using bovine serum albumin as standard. The spinal cord, cortex, and
brainstem specimens were collected and frozen at −80 °C until the
time of testing.
2.9. Statistical analysis
Datawere expressed asmean± standard error of themean. To eval-
uate behavior parameters (EPM and OF) across groups, one-way
ANOVA followed by SNK was performed at different timepoints (24 h
and 7 days) after the last tDCS session. One-way analysis of variance
(ANOVA) followed by Student–Newman–Keuls (SNK) was also con-
ducted to compare all groups for BDNF levels. P-values of less than
0.05 were reported as statistically signiﬁcant.
3. Results
Previous data from our group showed that tDCS was able to revert
the mechanical and thermal hyperalgesia in neuropathic pain induced
by the CCI model (Cioato et al., 2014).
3.1. Open ﬁeld test
TheANOVA for phase I of the OF test showed a between-group effect
on the number of line crossings (F(6,62) = 3.76, P b 0.05). In addition,
there was an increase in this parameter in the NpT group compared to
the Np group (F(6,62) = 3.76, P b 0.05). No effect was found on the
other parameters (Fs b 1.60, P N 0.05 for all).
Considering phase II of the OF test, the ANOVA showed differences
between groups in the total number of crossings (F(5,64) = 16.06,
P b 0.05), the latency to leave the ﬁrst quadrant (F(5,64) = 26.06,
P b 0.05), and the number of rearings (F(5,64) = 24.05, P b 0.05). The
NpT group had a higher number of line crossings than groups
Np (F(5,64) = 16.06, P b 0.05) and NpS (F(5,64) = 16.06, P b 0.05). The
NpT group showed a shorter latency to leave the ﬁrst quadrant com-
pared to groups Np (F(5,64) = 26.06, P b 0.05) and NpS (F(5,64) = 26.06,
P b 0.05). Similarly, rearing activity in the NpT group was greater than
that in groups Np (F(5,64) = 24.05, P b 0.05) and NpS (F(5,64) = 24.05,
P b 0.05). There was no effect on the other parameters (Fs b 2.96.
P N 0.05 for all) (Fig. 1).
3.2. Elevated plus-maze test
For phase I of the EPM test, one-way ANOVA showed that NpT and
NpS spent less time in the closed arms (F(5,53) = 5.82, P b 0.05) com-
pared to the overall mean for the Np groups. Additionally, the NpT
and NpS groups had increased time in the open arms compared to the
Np group (F(5,53)=6.43, P b 0.05) (Fig. 2). Considering theNPHDmove-
ments, the NpT and NpS groups had higher means in relation to the Np
group (F(5,53)= 5.32, P b 0.05). There was no effect on the other param-
eters (Fs b 4.86; P N 0.05 for all) (Fig. 2).
During EPM test II, theNpT group showed increased time in the open
arms compared to the Np (F(5,59) = 5.29, P b 0.05) and NpS groups
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Fig. 1. Open ﬁeld test. Data expressed asmean± SEM, n=21–24 animals/group. Ss (sham
surgery); SsS (sham surgery + sham tDCS); SsT (sham surgery + tDCS); Np (Neuropathic
pain); NpS (neuropathic pain + sham tDCS); NpT (neuropathic pain + tDCS). Group anal-
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⁎ signiﬁcant difference in relation to Ss, SsS, SsT and NpT groups, P b 0.05.
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compared to Np and NpS (all Fs b 4.69, P b 0.05). Further, the NpT
group time was decreased in the closed arms compared to Np and
NpS (F(5,59) = 5.25, P b 0.05). No differences were observed between
groups NpS and Np (F(5,59) = 5.29, P b 0.05). The NpT group showed in-
creased frequency of NPHD movements in relation to the Np and NpS
groups (F(5,59) = 3.88, P b 0.05). Interestingly, there was no signiﬁcant
difference between groups Np and NpS compared to all sham groups
(Ss, SsS, and SsT) (F(5,59) = 3.88, P N 0.05). There was no signiﬁcant dif-
ference in the other parameters (all Fs b 4.78; P N 0.05) (Fig. 2).3.3. Peripheral and central BDNF levels
In phase I, serum BDNF levels were not signiﬁcantly different be-
tween groups (F(5,34) = 0.88, P N 0.05). By contrast, in phase II, serum
BDNF levels were decreased in the NpT group compared to the others
(F(5,33) = 2.89, P b 0.05).
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(F(5,27) = 0.85, P N 0.05) in phase I. However, NpT showed an increase
in phase II compared to the other groups (F(5,27) = 5.82, P b 0.05)
(Fig. 3).
In phase I, cerebral cortex BDNF levels were signiﬁcantly de-
creased in the NpT group in relation to the other groups (F(5,30) =
6.12, P b 0.05). However, there was no signiﬁcant difference between
groups in phase II (F(5,30) = 2.50, P N 0.05).
Brainstem BDNF levels were reduced in phase I in the NpT group
compared to the others (F(5,30) = 9.06, P b 0.05). Furthermore, an
increase was noted in the NpS group compared to the other Np groups
(F(5,30)= 9.06, P b 0.05). In phase II, levels were lower in the NpT group
relative to the other groups (F(5,30)=19.14, P b 0.05) andNp showed an
increase compared to the other groups (F(5,30) = 19.14, P b 0.05). The
NpS group exhibited decreased levels in comparison to the Np group
(F(5,30) = 19.14, P b 0.05) (Fig. 3).
4. Discussion
This study shows for the ﬁrst time the effect of tDCS on the reversal
of behavioral alterations induced by the neuropathic pain model. Such
effect was indicated by reversion of the decreased locomotor and ex-
ploratory activities and increased anxiety-like behavior that had been
induced by that model 14 days following CCI surgery. Those particular
types of behavior are characteristic of persistent neuropathic pain
model (Zurowski et al., 2012).
The CCI animals showed a decrease in locomotor and exploratory ac-
tivities in phase II, corroborating a study that showed the same results
after 3 weeks of the neuropathic pain surgical procedure in rats(Roeska et al., 2008; Seminowicz et al., 2009). In addition, those animals
exhibited a longer latency to leave the ﬁrst quadrant. Walsh and
Cummins (1976) suggested that the output latency to leave the ﬁrst
quadrant is a behavior associatedwith emotional factors, whichmay in-
dicate an increase in anxiety-like behaviors (Stanford, 2007; Walsh
and Cummins, 1976). Most importantly, tDCS treatment reverted
those CCI-induced effects; therefore, we can suggest that this effect
could have resulted from the action of tDCS on cortical areas involved
in the pain matrix, such as the thalamus; anterior cingulate cortex
(ACC); insular cortex; frontal, premotor, primary sensory and motor
cortices (Moseley, 2003; Vaseghi et al., 2015; Zaghi et al., 2009). Addi-
tionally, previous studies from our group using chronic inﬂammation
(Laste et al., 2012) and hyperalgesia induced by chronic restraint stress
models (Spezia Adachi et al., 2012) showed an antinociceptive effect of
cortical stimulation by tDCS. Beyond the analgesic effect, human studies
with tDCS have shown effects on motor control, stress, and depression,
which could justify our results (Gonçalves, 2012; Nitsche et al., 2009a;
Orban de Xivry and Shadmehr, 2014).
Adequate locomotor activity results from the interaction of several
neurotransmitters (Kandasamy, 2000), such as those in the opioid sys-
tem, which is an important modulator of the descending pathway of
pain. The opioid system could be implicated in this behavior as well as
in the pain suppression mechanism (Fields, 2004). The involvement of
the opioid system is demonstrated by the administration of the opioid
receptor antagonist naloxone, which reduces the locomotor and explor-
atory activities in naive rats (File, 1980). In support of those data, it has
been found that μ-opioid receptor knockout mice show less exploratory
activity (Yoo et al., 2003). According to Taylor et al. (2012), brain mod-
ulation by electrical stimulation can induce changes to the endogenous
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duced an increase in endogenous opioid activity in patients with chron-
ic pain (Maarrawi et al., 2007; Taylor et al., 2012), and anodal tDCS
enhanced endogenous opioid release in healthy humans (DosSantos
et al., 2012). Thus, we can suggest that a single pathway is involved in
tDCS behavior modulation effect on the opioid system.
Another hypothesis is that the descending projections of the pre-
frontal cortex exert excitatory control on the midbrain dopaminergic
neurons, triggering dopamine release in the ventral striatum and nucle-
us accumbens (NAc) (Jackson et al., 2001). Furthermore, neurochemical
and electrophysiological studies have demonstrated that prefrontal cor-
tex stimulation increases dopamine release in the NAc and increases
burst ﬁring of midbrain dopaminergic neurons, thereby corroborating
this interaction (Karreman and Moghaddam, 1996; Murase et al.,
1993; Taber and Fibiger, 1995; Tong et al., 1996). The stimulation of do-
paminergic neurons increases locomotor activity (Fishman et al., 1983),
which proves the importance of these neurons to themodulation of this
behavior. The use of tDCS in humans is known to increase the levels of
extracellular dopamine (Tanaka et al., 2013). Arguably, then, tDCS treat-
mentmodulates the dopaminergic system in the frontal cortex, promot-
ing dopamine release and consequently improving locomotor and
exploratory activities of CCI rats.
Neuropathic pain, as a chronic stressor, induces both physiological
and psychological changes, which may lead to multiple neuropsychiat-
ric disorders (Asmundson and Katz, 2009). Although the latency to
leave the ﬁrst quadrant as measured by the OF test is not a speciﬁc var-
iable to assess anxiety, we noted that neuropathic pain induces in-
creased latency, which corroborates the anxiety-like behavior assessed
by the EPM. In animal studies, the EPM is a validated instrument to eval-
uate anxiety-like behaviors (Hogg, 1996). The treatment with tDCS
reverted the CCI-induced increase in this parameter. Animal studies in-
vestigating the effect of neuropathic pain in anxiety-like behaviors are
inconsistent. These behaviors are observed in the EPM test with rats
up to 2 weeks after the CCI procedure (Kontinen et al., 1999); after
spared nerve injury, this effect is maintained for several weeks
(Seminowicz et al., 2009). Wallace et al. (2007) used the model of
HIV-induced peripheral neuropathy and showed anxiety-like behaviors
up to 2weeks after induction. In addition, CCI rats displayed anxiety-like
behaviors in the EPM up to 3 weeks after the injury, but these effects
were not found using the model of partial sciatic nerve ligation (PSNL)
(Roeska et al., 2008; Wallace et al., 2007). In our study, the CCI rats de-
veloped anxiety-like behavior up to at least 21 days after surgery; an ef-
fect that was reversed after tDCS treatment indicating an anxiolytic
effect of tDCS.
After 48 h of tDCS treatment completion, the neuropathic pain ani-
mals that received real tDCS (NpT) showed a decrease in anxiety-like
behaviors. Nevertheless, the NpS group showed a similar effect. We
could suggest that the body restraint necessary for tDCS application
may be implicated in this ﬁnding, since it is considered a stress model.
It is known that stress situations can activate the endogenous opioid
system and promote behavioral changes, such as diminished anxiety
levels a protective mechanism of body resistance to stress (Colasanti
et al., 2011). At 7 days after the end of tDCS treatment, an anxiolytic
tDCS effect was also observed. This effect could be related to tDCS action
on different neurotransmitter systems, such as the glutamatergic
(Radman et al., 2009), GABAergic (Nitsche et al., 2004b), opioid
(DosSantos et al., 2012), cholinergic (Kuo et al., 2007), serotonergic
(Nitsche et al., 2009b), and catecholamine (Nitsche et al., 2004a). The
periaqueductal gray (PAG) and the hippocampus (Drake et al., 1999)
show a high density of opioid receptors and have been extensively stud-
ied in relation to anxiolytic states. Morphine administered directly into
the PAG showed an anti-stress effect, which was antagonized by nal-
trexone (an opioid antagonist more selective to μ receptors) and mim-
icked by DAMGO, an agonist of the μ-selective receptor (Anseloni
et al., 1999; Drake et al., 1999). The μ-opioid receptors located in the
dorsal hippocampus are involved in anxiolytic behavior; in fact,opioid-deﬁcient mice are more anxious than naive animals (Hayase
et al., 2006). Therefore, we can also postulate that the reduction in
anxiety-like behaviors found in our study may be related to an effect
of tDCS treatment on the opioid system.
Interestingly, the NpS group showed a modulatory effect of
brainstem BDNF levels. This result could be due to a synergistic effect
of pain and stress caused by the restraint induced by the experimental
model. It is known that restraint-induced stress modulates BDNF ex-
pression (Autry and Monteggia, 2012); thus, our data may indicate a
functional impairment in its regulation in the medium term (48 h
after tDCS treatment completion), since this effect was reversed over
the long term (7 days post-tDCS treatment). These results corroborate
the data from Marmigère et al. (2003), who found that restrained rats
had a rapid increase in BDNF levels in the CNS (Marmigère et al., 2003).
The present study also demonstrated that CCI decreased BDNF levels
in the brainstem after 23 days post-surgery (48 h after the end of tDCS
treatment) and increased those levels after 30 days post-surgery
(7 days after tDCS treatment completion). Interestingly, tDCS reduced
brainstem BDNF levels in both phases (I and II) and in phase I in the
cerebral cortex, while in phase II tDCS decreased serum and increased
spinal cord BDNF levels.
In some studies, BDNF is used as a biological marker of clinical con-
ditions such as anxiety, depression, ﬁbromyalgia, and schizophrenia
(Kurita et al., 2012; Nurjono et al., 2012). However, the relationship be-
tween BDNF levels and anxiety disorders is controversial: BDNF levels
appear to be either reduced increased, or not signiﬁcantly altered in pa-
tients with anxiety disorders (Bonne et al., 2011; Dell'Osso et al., 2009;
Dos Santos et al., 2011; Molendijk et al., 2012; Wang et al., 2011). In an
animal study, using genetically engineered mice for BDNF overexpres-
sion resulted in elevated anxiety (Govindarajan et al., 2006). Polymor-
phism of BDNF (Met/Met) was associated with increased anxiety-
related behaviors in mice, thus suggesting a key role of genetic predis-
position in anxiety and depressive disorders (Chen et al., 2006).
Chronic neuropathic pain situations can be associated directly with
high levels of anxiety symptoms (Wallace et al., 2007). Therefore, the
analgesic effect of tDCS can contribute to the management of anxiety
symptoms in these conditions. The reduction in anxiety-like behaviors
may be related to the reversion of brainstem BDNF levels after tDCS
treatment. This neurotrophin has also been implicated in the control
of nociceptive neurotransmission and in the behavioral pharmacologi-
cal and physiological process (Kumamaru et al., 2008). BDNF is involved
in the synaptic plasticity and survival of neurons (Siniscalco et al., 2011).
The underlying effect of tDCS on BDNF regulation mechanisms has not
been fully elucidated. The increased in the spinal cord BDNF levels ob-
served in this study can be related to the synaptic plasticity (Baker-
Herman et al., 2004). The role of BDNF in pain is still unclear: studies
have shown that attenuation in pain behavior is associated with de-
creased BDNF levels; however, there is evidence that BDNF may play
an antinociceptive role in different settings (Coull et al., 2005). Addi-
tionally, study recently published by our research group demonstrated
that tDCS was able to decrease BDNF levels in the structures involved
in the descending systems only in unstressed animals (Spezia Adachi
et al., 2015). Interestingly, corroborating our results, increase of BDNF
levels has been found in neuroplastic events associated with chronic
pain conditions (Ranieri et al., 2012). In this way, tDCS might be an al-
ternative treatment to prevent central neuronal alterations presents in
the neuropathic pain.
Increased expression of BDNF regulates NMDA and AMPA receptors
and facilitates the induction and maintenance phases of long-term po-
tentiation (LTP) (Caldeira et al., 2007). Another role of BDNF is that it
is also responsible for regulating the organization of inhibitory synapses
(Swanwick et al., 2006). It has been demonstrated that BDNF also acts
on presynaptic terminals to enhance the release of the inhibitory neuro-
transmitter gamma-aminobutyric acid (GABA), an effect that has
been suggested to cause indirect suppression through excitation by
GABAergic signaling (Malcangio and Lessmann, 2003). Although tDCS
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bral cortex (Fig. 3C) and to increase these levels in the spinal cord
(Fig. 3B), such ﬁndings may indicate that tDCS activates speciﬁc path-
ways (i.e., descending systems) and does not cause general brain activa-
tion; in fact, those alterationswere found at speciﬁc timepoints. As tDCS
treatment induces neuronal changes by activating various neurotrans-
mitters, we believe that this variability in BDNF levels in different CNS
structures could be due to its extensive action in neural network circuits
that activate a variety of signaling pathways.
5. Conclusion
The present data indicate that tDCS reverses the behavioral alter-
ations induced by chronic neuropathic pain, as indexed by changes in
locomotor and exploratory activities and anxiety-like behaviors. It is
worth noting that tDCS treatment also reversed the increase in BDNF
brainstem levels that had been induced by chronic neuropathic pain.
In addition, tDCS treatment alters BDNF levels in serum and in different
CNS regions independently of the chronic neuropathic pain. The vari-
ability of tDCS effects on the levels of BDNF in different structures is
probably due to activation of different signaling pathways. Further stud-
ies are warranted to evaluate the neurotransmitter system (opioidergic,
dopaminergic, glutamatergic, and GABAergic systems) and thereby pro-
vide a better understanding of the tDCS mechanisms in the anxiety dis-
orders induced by the neuropathic pain model.
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